Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.

Identifieur interne : 000545 ( Ncbi/Merge ); précédent : 000544; suivant : 000546

Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.

Auteurs : Vince Pozsgay [États-Unis] ; Joanna Kubler-Kielb ; Rachel Schneerson ; John B. Robbins

Source :

RBID : pubmed:17726093

Descripteurs français

English descriptors

Abstract

Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.

DOI: 10.1073/pnas.0706969104
PubMed: 17726093

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:17726093

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</title>
<author>
<name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
<affiliation wicri:level="2">
<nlm:affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
</author>
<author>
<name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</author>
<author>
<name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17726093</idno>
<idno type="pmid">17726093</idno>
<idno type="doi">10.1073/pnas.0706969104</idno>
<idno type="wicri:Area/PubMed/Corpus">002164</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002164</idno>
<idno type="wicri:Area/PubMed/Curation">002164</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002164</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002066</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002066</idno>
<idno type="wicri:Area/Ncbi/Merge">000545</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</title>
<author>
<name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
<affiliation wicri:level="2">
<nlm:affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
</author>
<author>
<name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</author>
<author>
<name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
</author>
</analytic>
<series>
<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antibodies (blood)</term>
<term>Antibodies (immunology)</term>
<term>Cattle</term>
<term>Immunogenetics</term>
<term>Mice</term>
<term>Molecular Structure</term>
<term>O Antigens (biosynthesis)</term>
<term>O Antigens (chemistry)</term>
<term>O Antigens (classification)</term>
<term>O Antigens (immunology)</term>
<term>Shigella dysenteriae (genetics)</term>
<term>Shigella dysenteriae (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Anticorps (immunologie)</term>
<term>Anticorps (sang)</term>
<term>Antigènes O ()</term>
<term>Antigènes O (biosynthèse)</term>
<term>Antigènes O (immunologie)</term>
<term>Bovins</term>
<term>Immunogénétique</term>
<term>Shigella dysenteriae (génétique)</term>
<term>Shigella dysenteriae (immunologie)</term>
<term>Souris</term>
<term>Structure moléculaire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en">
<term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Antibodies</term>
<term>O Antigens</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Antigènes O</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Anticorps</term>
<term>Antigènes O</term>
<term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Anticorps</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cattle</term>
<term>Immunogenetics</term>
<term>Mice</term>
<term>Molecular Structure</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Antigènes O</term>
<term>Bovins</term>
<term>Immunogénétique</term>
<term>Souris</term>
<term>Structure moléculaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17726093</PMID>
<DateCompleted>
<Year>2007</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>104</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</ArticleTitle>
<Pagination>
<MedlinePgn>14478-82</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pozsgay</LastName>
<ForeName>Vince</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kubler-Kielb</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schneerson</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robbins</LastName>
<ForeName>John B</ForeName>
<Initials>JB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>08</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019081">O Antigens</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007125" MajorTopicYN="Y">Immunogenetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019081" MajorTopicYN="N">O Antigens</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012762" MajorTopicYN="N">Shigella dysenteriae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2007</Year>
<Month>8</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2007</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2007</Year>
<Month>8</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17726093</ArticleId>
<ArticleId IdType="pii">0706969104</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.0706969104</ArticleId>
<ArticleId IdType="pmc">PMC1955462</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Vaccine. 2006 Feb 6;24(6):716-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16233938</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2006 Feb 1;176(3):1686-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16424198</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Org Chem. 2005 Aug 19;70(17):6987-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16095333</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Org Chem. 1998 Aug 21;63(17):5983-5999</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11672203</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bull World Health Organ. 1999;77(8):651-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10516787</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1934 Oct 31;60(5):599-617</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19870325</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carbohydr Res. 2006 Jul 24;341(10):1408-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16650395</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microbiology. 2007 Jan;153(Pt 1):139-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17185542</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioconjug Chem. 1991 Nov-Dec;2(6):458-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1805944</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microb Pathog. 1986 Jun;1(3):299-306</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2469932</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 1992 Aug;15(2):346-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1381621</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Biochem. 1993 Apr 1;213(1):573-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7682945</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2003 Nov;9(11):1471-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14718096</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Glycobiology. 2001 Nov;11(11):945-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11744629</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Jul 23;305(5683):522-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15273395</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1980 Aug 1;152(2):361-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6967514</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1993 Dec 5;268(34):25797-802</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7503987</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1971 Dec;33(6):988-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">5316354</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anal Biochem. 1986 May 15;155(1):95-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3717562</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carbohydr Res. 2006 Sep 4;341(12):2037-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16458277</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioconjug Chem. 1997 May-Jun;8(3):424-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9177850</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microb Pathog. 1986 Jun;1(3):307-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2469933</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 Aug 30;362(9385):705-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12957094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Immunol. 1996 Nov;33(16):1217-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9129157</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Biochem. 1976 Jul 15;66(3):559-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8314</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Immun. 1993 Sep;61(9):3678-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8359890</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5194-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10220442</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Immun. 1991 Dec;59(12):4450-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1937803</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Maryland</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
<name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
<name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</noCountry>
<country name="États-Unis">
<region name="Maryland">
<name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000545 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000545 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:17726093
   |texte=   Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:17726093" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021